Evoke Pharma Inc
EVOKHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $10.2M | $5.2M | $2.5M | $1.6M | $23,020 | — |
| Operating income | −$5.2M | −$7.4M | −$7.8M | −$8.2M | −$13.0M | −$7.2M |
| Net income | −$5.4M | −$7.8M | −$5.4M | −$8.5M | −$13.2M | −$7.1M |
| Total assets | $17.5M | $7.1M | $11.9M | $10.6M | $9.4M | $6.4M |
| Total liabilities | $10.5M | $9.6M | $7.8M | $7.0M | $12.6M | $2.0M |
| Equity | $7.0M | −$2.6M | $4.1M | $3.6M | −$3.2M | $4.4M |
| EPS (diluted) | $-2.81 | $-27.97 | $-2.62 | $-3.18 | — | — |
| Shares out. | 8.5M | 3.3M | 32.9M | 32.4M | 24.4M | 17.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −50.8%
- Net margin
- −52.2%
- Return on equity
- −76.0%
- Return on assets
- −30.6%
- Return on capital (ROCE)
- −72.9%
- Liabilities / assets
- 59.8%
- Debt / equity
- 1.49×
- Book value / share
- $0.83
- Revenue growth (YoY)
- 97.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -22.69distress
- Accruals / assets
- 0.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Nantahala Capital Management, LlcActivist (13D)Dec 19, 2025
- Morgan StanleyPassive (13G)Dec 5, 2025
- Klein Roger M.Activist (13D)Nov 12, 2025
- Lytton Laurence WPassive (13G)May 15, 2025
- Bleichroeder LpPassive (13G)Mar 24, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Dec 15, 2025 | 10,911 | 1.0 | +56.2% |
| Nov 28, 2025 | 6,987 | 1.0 | -60.6% |
| Nov 14, 2025 | 17,746 | 1.0 | +109.8% |
| Oct 31, 2025 | 8,458 | 1.0 | -52.0% |
| Oct 15, 2025 | 17,639 | 1.0 | -58.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 17, 2025
- Results of operationsNov 13, 2025
- Entered a material agreement · Director / officer change · Other material eventNov 4, 2025
- Results of operationsAug 14, 2025
- Other material eventAug 6, 2025
- Other material eventJul 9, 2025
- Shareholder voteMay 22, 2025
- Results of operationsMay 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.